/Thermo%20Fisher%20Scientific%20Inc_%20site%20magnified-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Although Thermo Fisher Scientific has lagged behind the broader S&P 500 index over the past year, analysts remain confident in its long-term growth prospects.
Bio-Rad Laboratories, Inc.’s BIO solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees increased...
/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Bio-Techne has underperformed the biotechnology industry over the past year, but analysts are highly optimistic about the stock’s prospects.
/Thermo%20Fisher%20Scientific%20Inc_%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
While Thermo Fisher Scientific has underperformed the broader medical device industry recently, analysts remain optimistic about the company's future outlook.
Bio-Rad Laboratories, Inc. BIO posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year...